During the past decade, Lynn Cancer Institute Center for Hematology Oncology conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 5 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Lynn Cancer Institute Center for Hematology Oncology" #1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator and "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Lynn Cancer Institute Center for Hematology Oncology" are "Prostate Cancer" (2 trials), "Lung Cancer - Non Small Cell Squamous" (1 trials), "Non Squamous Lung Cancer" (1 trials), "Non-Small-Cell Lung Adenocarcinoma" (1 trials) and "Non-small Cell Lung Cancer Metastatic" (1 trials). Many other conditions were trialed in "Lynn Cancer Institute Center for Hematology Oncology" in a lesser frequency.

Most popular intervention types in "Lynn Cancer Institute Center for Hematology Oncology" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Ipilimumab" (2 trials), "Carboplatin" (1 trials), "Docetaxel" (1 trials) and "Enzalutamide" (1 trials). Other intervention names were less common.

The vast majority of trials in "Lynn Cancer Institute Center for Hematology Oncology" are 3 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Lynn Cancer Institute Center for Hematology Oncology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Lynn Cancer Institute Center for Hematology Oncology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Lynn Cancer Institute Center for Hematology Oncology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".